Patent: 6,472,373

« Back to Dashboard

Summary for Patent: 6,472,373

Title:	Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
Abstract:	Methods for treating an antiviral treatment naive patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving administering a therapeutically effective amount of a combination therapy of ribavirin and interferon-alpha for a time period of from 20 up to 50 weeks are disclosed.
Inventor(s):	Albrecht; Janice K. (Winter Park, FL)
Assignee:	Schering Corporation (Kenilworth, NJ)
Application Number:	09/311,487
Patent Claims:	see list of patent claims

United States Patent 6,472,373: Claims, Patent Expiration, Litigation Risk, and HCV Treatment Landscape

United States Patent 6,472,373 claimed genotype- and baseline viral-load-guided treatment durations for chronic hepatitis C using ribavirin with interferon-alpha. Its central commercial concept was 48-week treatment for genotype 1 patients with higher viral load and approximately 24-week treatment for lower-risk genotype 1 or genotype 2/3 patients.

The patent issued on October 29, 2002, from an application claiming priority to a 1998 filing. Its statutory patent term expired in 2018, subject to any applicable patent-term adjustment. It therefore does not create current U.S. exclusionary rights against direct-acting antiviral products, generic ribavirin, peginterferon products, or current HCV treatment regimens. Its primary present value is historical: it documents an early response-guided treatment strategy and illustrates the patentability and enforcement problems associated with clinical treatment algorithms.

What does United States Patent 6,472,373 cover?

The patent covers methods that select chronic HCV patients according to genotype and initial viral load, then assign different durations of combination treatment with ribavirin and interferon-alpha.

Claim group	Patient population	Treatment duration	Core limitation
Claims 1-8	Genotype 1, viral load above 2 million copies/mL	About 40-50 weeks	Ribavirin plus interferon-alpha
Claims 1-8	Genotype 1, viral load at or below 2 million copies/mL	About 20-24 weeks	Ribavirin plus interferon-alpha
Claim 2	Genotype 1	About 48 weeks	Ribavirin at about 800-1,200 mg/day
Claims 3-8	Genotype 1	As specified in claim 1	Defined interferon-alpha products and dose ranges
Claim 9	Genotype 1, high viral load	48 weeks	Ribavirin plus interferon-alpha
Claim 9	Genotype 1, low viral load	At least about 24 and up to about 48 weeks	Ribavirin plus interferon-alpha
Claims 10-12	Genotype 2 or 3	About 20-24 weeks or at least about 24 weeks	Ribavirin plus interferon-alpha
Claims 13-19	Genotype 1, 2 or 3	As incorporated from claims 9-11	Interferon and ribavirin dose limitations

The patent does not claim a new chemical compound, a new ribavirin formulation, a new interferon molecule, or a new assay. It claims a treatment-selection protocol.

The patent identifies interferon-alpha broadly, including conventional interferon alpha-2a, interferon alpha-2b, consensus interferon, purified interferon-alpha products, pegylated interferon alpha-2a and pegylated interferon alpha-2b. The ribavirin dose in several dependent claims is approximately 800 to 1,200 mg per day.

How are the claims structured?

Independent claims 1 and 9

Claim 1 creates two treatment branches for genotype 1 patients:

1. Initial HCV-RNA above 2 million copies/mL: treat for about 40 to 50 weeks.
2. Initial HCV-RNA at or below 2 million copies/mL: treat for about 20 to 24 weeks.

Claim 9 narrows the first branch to 48 weeks but expands the low-viral-load branch to a range from at least approximately 24 weeks to approximately 48 weeks.

The two claims overlap. A low-viral-load genotype 1 patient treated for 24 weeks can fall within both claim 1 and claim 9. That overlap does not necessarily invalidate either claim, but it reduces claim clarity and creates interpretation issues around the relationship between the duration ranges.

Independent claims 10 and 11

Claims 10 and 11 address genotype 2 or 3 patients:

• Claim 10 covers treatment for at least about 20 to about 24 weeks.
• Claim 11 covers treatment for at least about 24 weeks.

The language overlaps at approximately 24 weeks. Claim 12 adds a 24-week regimen and ribavirin dosing of about 800 to 1,200 mg per day.

Dependent claims 3-8 and 13-18

These claims define the interferon component and dose. They cover conventional and pegylated interferons, including:

• Interferon alpha-2a;
• Interferon alpha-2b;
• Consensus interferon;
• Purified interferon-alpha products;
• Pegylated interferon alpha-2a; and
• Pegylated interferon alpha-2b.

The broad product language increases theoretical coverage but also makes the claims dependent on proof that the accused treatment used a qualifying interferon product and met the specified dosing range.

What patent protects the genotype- and viral-load-guided HCV regimen?

United States Patent 6,472,373 is the principal patent directed to the treatment-duration algorithm described in the supplied claims. Its claims focus on:

• Treatment-naive status;
• Chronic HCV infection;
• HCV genotype;
• Baseline HCV-RNA level;
• Ribavirin plus interferon-alpha; and
• Treatment duration.

The patent does not independently control the underlying active ingredients. Ribavirin, interferon-alpha, pegylation technologies, injectable formulations, manufacturing processes, and combination products were protected, where applicable, by separate patent families.

This distinction matters. A product could have been covered by a compound, formulation, or biologic manufacturing patent without practicing the duration-selection method. Conversely, a physician or sponsor could theoretically practice the method without infringing a formulation patent if the underlying product patent had expired or did not cover the product used.

When did United States Patent 6,472,373 lose exclusivity?

Event	Date
Priority and filing period	1998
Patent issued	October 29, 2002
Expected 20-year term from earliest nonprovisional filing	2018
Statutory expiration	November 30, 2018
Current status	Expired; no live U.S. patent exclusivity

The patent’s term was governed by the post-June 8, 1995 patent-term framework, which generally provides 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment and other statutory provisions. The patent is no longer an enforceable barrier to U.S. market entry.

The patent also does not provide current regulatory exclusivity. Patent expiry and FDA exclusivity are separate legal concepts. Any FDA exclusivity associated with peginterferon or ribavirin products expired many years before the patent’s statutory end date.

What were the principal legal vulnerabilities in the claims?

Obviousness under Section 103

The strongest historical validity issue was obviousness. By the relevant priority period, clinicians already used ribavirin with interferon-alpha, recognized genotype-dependent response differences, measured HCV-RNA, and commonly treated patients for approximately 24 or 48 weeks.

The asserted inventive step was the specific selection rule:

• Longer treatment for genotype 1 patients with higher baseline viral load.
• Shorter treatment for genotype 1 patients with lower baseline viral load.
• Approximately 24-week treatment for genotype 2 or 3 patients.

A challenger could argue that the claims merely combine known clinical variables and known treatment durations. The patentee’s counterargument would be that the particular viral-load threshold and treatment-duration allocation produced an unexpected balance between sustained virologic response, treatment burden, and relapse risk.

The patent’s strength therefore depended heavily on the clinical evidence supporting the 2 million copies/mL threshold and the selected duration ranges.

Written description and enablement

The claims cover numerous interferon products, dosing schedules, and patient groups. A validity challenge could examine whether the specification demonstrated possession of the full breadth of:

• Conventional and pegylated interferons;
• Multiple dosing schedules;
• Genotypes 1, 2 and 3;
• The stated viral-load threshold; and
• All claimed treatment-duration ranges.

Broad claims supported by limited examples can face written-description and enablement challenges. This issue would have been particularly relevant to the claims covering both peginterferon products when clinical data were more limited at the time of filing.

Indefiniteness and claim construction

The claims use terms such as:

• "About";
• "Therapeutically effective amount";
• "At least about";
• "Initial viral load";
• "Antiviral treatment naive"; and
• "Greater than 2 million copies/mL."

These terms are common in pharmaceutical patents, but the threshold creates technical questions. HCV-RNA results varied by assay platform, calibration standard, specimen handling, and conversion between copies/mL and IU/mL. A patient could measure above the threshold with one assay and below it with another.

The phrase "about 20 to about 24 weeks" also creates a boundary issue. Claims 10 and 11 overlap at approximately 24 weeks, while claims 1 and 9 use different treatment ranges for low-viral-load genotype 1 patients.

Direct infringement proof

The claims require patient identification and treatment. A method-of-treatment plaintiff would need to establish that an accused party:

1. Treated a patient with chronic HCV;
2. Knew or determined the patient was antiviral-treatment naive;
3. Determined the HCV genotype;
4. Measured the initial viral load using the required type of qPCR measurement;
5. Administered ribavirin and interferon-alpha; and
6. Followed the required duration and dose limitations.

A product manufacturer would not necessarily directly infringe merely by selling ribavirin or peginterferon. Liability would depend on the evidence of inducement, including labeling, promotional materials, clinical protocols, and the specific instructions provided to physicians.

What was the Orange Book status of the patent?

United States Patent 6,472,373 was a method patent covering a clinical regimen rather than the active ingredient of a drug. Its practical Orange Book relevance was limited.

The Orange Book generally lists patents submitted by an NDA holder that claim the drug substance, drug product, or an approved method of use. The patent’s relevance to Orange Book-listed products would depend on whether the NDA holder submitted it and whether FDA accepted the corresponding method-of-use listing.

For ribavirin and interferon products, the principal commercial patent issues historically concerned:

• Ribavirin compound and formulation rights;
• Pegylated interferon composition and conjugation rights;
• Injectable formulation patents;
• Manufacturing and purification patents; and
• Approved methods of use.

The existence of an issued patent did not automatically create an Orange Book listing. Conversely, an Orange Book listing did not extend the patent’s expiration date.

Did the patent generate Paragraph IV challenges?

The patent’s treatment-method claims could have been relevant to an ANDA applicant seeking approval for ribavirin or an interferon product. A Paragraph IV certification would have required the applicant to assert that the patent was invalid, unenforceable, or not infringed.

The commercial significance was limited for several reasons:

• The patent expired in 2018.
• Ribavirin had long been marketed through multiple product and regulatory pathways.
• Peginterferon products had separate biologic and product-specific patent estates.
• ANDA applicants could use a section viii statement to carve out a patented method of use where the labeling permitted a non-infringing use.
• A method claim directed to treatment duration does not necessarily block approval of the underlying drug.

No current Paragraph IV strategy should treat Patent 6,472,373 as a live barrier. Any historical Paragraph IV dispute must be analyzed through the specific defendant, product, filing date, and asserted patent claims.

What patent litigation affected the HCV interferon and ribavirin market?

The important HCV patent disputes of the period generally involved broader commercial assets than the treatment-duration claims in Patent 6,472,373. Litigation risk centered on:

Technology	Typical rights at issue	Commercial effect
Ribavirin	Compound, formulation and combination-use patents	Generic entry and labeling restrictions
Conventional interferon-alpha	Composition, production and therapeutic-use rights	Product and licensing disputes
Peginterferon alpha-2b	PEG conjugation, composition, dosing and manufacturing	Competition involving Merck’s PegIntron
Peginterferon alpha-2a	PEGylated interferon composition and formulation	Competition involving Roche’s Pegasys
HCV treatment protocols	Genotype, viral-load and duration-based methods	Method-of-use enforcement

Patent 6,472,373 was narrower than a compound or pegylation patent because it required a specific clinical decision and combination regimen. Its value was greatest while interferon-based treatment was standard of care. The emergence of direct-acting antivirals sharply reduced the commercial relevance of interferon-duration patents.

How strong was the patent estate?

Strengths

• The claims identified a concrete patient-selection threshold.
• The method linked genotype and viral load to defined treatment duration.
• The claims covered commercially important interferon products.
• The regimen reflected clinically meaningful treatment decisions.
• The patent could have supported method-of-use enforcement against labeling or clinical protocols that expressly directed the claimed treatment.

Weaknesses

• The underlying therapy was known.
• Genotype and viral load were established clinical variables.
• Twenty-four- and 48-week treatment periods were conventional in HCV care.
• The 2 million copies/mL threshold could vary across assays.
• "About" and overlapping duration ranges created claim-construction issues.
• Broad interferon and dosing language increased written-description and enablement exposure.
• The claims did not cover the newer DAA treatment architecture that replaced interferon.

Overall, the patent was historically meaningful but structurally narrower and more vulnerable than a patent covering a novel HCV compound, a proprietary DAA combination, or a core pegylation platform.

How does this patent compare with modern HCV patents?

Attribute	US 6,472,373	Modern DAA patent
Claimed subject matter	Patient selection and treatment duration	Chemical entity, fixed-dose combination, formulation or regimen
Active agents	Ribavirin plus interferon-alpha	Direct-acting antiviral agents
Biomarker	Genotype and baseline HCV-RNA	Genotype, resistance, cirrhosis and prior treatment may be relevant
Infringement evidence	Patient records and treatment instructions	Product identity, formulation, use and manufacturing evidence
Commercial leverage	Dependent on interferon standard of care	Often tied directly to the marketed product
Current status	Expired	Varies by patent and jurisdiction
Biosimilar relevance	Limited	Relevant only for biologic components
Generic risk	Historical ribavirin and interferon competition	Depends on compound and formulation expiry

The patent does not cover sofosbuvir, ledipasvir, velpatasvir, glecaprevir, pibrentasvir, grazoprevir, elbasvir, voxilaprevir or other DAA products. It cannot be used to block current all-oral DAA treatment.

What generic launch risks existed?

During the patent’s active term, generic launch risk depended on the product and the proposed label.

Ribavirin

A ribavirin applicant could face patent issues involving the product or an approved combination method. The applicant might avoid method claims through a carved-out label, provided the remaining label did not encourage the patented use.

Conventional interferon

Conventional interferon products faced biologic regulatory requirements and product-specific patent rights. A treatment-duration patent could matter if the proposed label expressly instructed genotype- and viral-load-based treatment durations.

Peginterferon

Peginterferon products presented greater formulation, composition and manufacturing complexity. A biosimilar or follow-on applicant would need to assess biologic patent families separately from Patent 6,472,373.

Current HCV products

There is no current generic launch risk arising from Patent 6,472,373. Its expiration removes the patent-specific risk, while current market access is governed by DAA patent families, regulatory exclusivity, manufacturing capability, licensing arrangements and supply contracts.

What geographic coverage did the patent have?

The patent provided rights only in the United States. International protection would have depended on national counterparts in the relevant jurisdictions. A U.S. expiration did not determine the status of corresponding patents in Europe, Japan, Canada, China or other countries.

For transaction or litigation analysis, the correct approach is jurisdiction-by-jurisdiction review of:

• National patent numbers;
• Earliest effective priority date;
• Patent-term adjustment or extension;
• Maintenance-fee status;
• Opposition or revocation proceedings;
• National claim scope; and
• Local treatment and product labeling.

No foreign patent can be presumed to have the same claims, term or enforceability as US 6,472,373.

What manufacturing and licensing barriers were relevant?

Patent 6,472,373 did not create a manufacturing monopoly. It claimed patient treatment, not the manufacture of ribavirin or interferon-alpha.

Manufacturing barriers historically arose from:

• Pegylation chemistry;
• Recombinant interferon expression systems;
• Protein purification;
• Sterile injectable formulation;
• Delivery-device compatibility;
• Quality-control assays; and
• Regulatory comparability requirements.

Licensing arrangements among pharmaceutical companies were more important for peginterferon commercialization than for the treatment-duration claims. Commercial parties had to separate rights in the interferon product from rights in the clinical regimen. A license to manufacture or sell peginterferon would not automatically grant rights under a separate method patent unless the agreement expressly covered that use.

Key Takeaways

• US 6,472,373 claimed genotype- and viral-load-based treatment durations for ribavirin plus interferon-alpha.
• The central threshold was an initial HCV-RNA level of 2 million copies/mL.
• Genotype 1 patients with higher viral load were assigned approximately 40-50 weeks, generally 48 weeks.
• Genotype 1 patients with lower viral load were assigned approximately 20-24 weeks, while claim 9 allowed 24-48 weeks.
• Genotype 2 or 3 patients were assigned approximately 20-24 weeks or at least approximately 24 weeks.
• The patent expired in 2018 and is not a current U.S. barrier to generic, biosimilar or DAA entry.
• Historical weaknesses included obviousness, assay-dependent viral-load thresholds, overlapping duration ranges and proof problems for method infringement.
• The patent did not cover the active ingredients themselves, pegylation technology, manufacturing processes or modern direct-acting antivirals.
• Current HCV freedom-to-operate analysis must focus on DAA compound, formulation, combination, manufacturing and method-of-use patent families.

FAQs About US Patent 6,472,373

Does US 6,472,373 cover Harvoni or other direct-acting antivirals?

No. The claims require ribavirin and interferon-alpha. They do not cover ledipasvir, sofosbuvir, velpatasvir or other DAA products.

Could a physician have infringed the patent by treating a genotype 1 patient for 48 weeks?

During the enforceable term, infringement would have required all claim elements, including treatment-naive status, genotype, viral-load measurement, the specified drug combination and treatment duration. Patent expiry eliminates prospective infringement liability.

Is the 2 million copies/mL threshold equivalent to a current HCV-RNA IU/mL threshold?

No automatic conversion applies. Copies/mL and IU/mL depend on assay calibration. The patent expressly uses copies/mL measured by qPCR, creating potential historical claim-construction and proof issues.

Are peginterferon biosimilars blocked by this patent?

No. The patent expired and did not claim the manufacture of peginterferon. Any biosimilar analysis would focus on separate composition, formulation, manufacturing and regulatory patents.

Does patent expiry eliminate every barrier to generic ribavirin or interferon entry?

No. It eliminates this patent as a barrier. Separate patents, regulatory requirements, biologic comparability standards, manufacturing rights, labeling restrictions and commercial agreements may still affect market entry.

References

1. United States Patent and Trademark Office. (2002). U.S. Patent No. 6,472,373, Methods for treating hepatitis C virus infection.
2. United States Code, 35 U.S.C. §§ 154, 271, 282, 283, 284.
3. U.S. Food and Drug Administration. (2004). Orange Book: Approved drug products with therapeutic equivalence evaluations.
4. U.S. Food and Drug Administration. (2001). Rebetol (ribavirin) prescribing information.
5. U.S. Food and Drug Administration. (2001). PegIntron (peginterferon alfa-2b) prescribing information.
6. U.S. Food and Drug Administration. (2002). Pegasys (peginterferon alfa-2a) prescribing information.
7. American Association for the Study of Liver Diseases and Infectious Diseases Society of America. (2014). HCV guidance: Recommendations for testing, managing, and treating hepatitis C.
8. Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. 66 (2012).

Details for Patent 6,472,373

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Hoffmann-la Roche Inc.	PEGASYS COPEGUS COMBINATION PACK	peginterferon alfa-2a and ribavirin		125083	June 4, 2004		2019-05-13
Schering Corporation A Subsidiary Of Merck & Co., Inc.	PEGINTRON/ REBETOL COMBO PACK	peginterferon alfa-2b and ribavirin		125196	June 13, 2008		2019-05-13